Clinical Trials
21 trialsNCT01962636 2026-05-20
Umbilical Cord Blood Transplantation Using a Myeloablative Preparative Regimen for Hematological Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT03333486 2025-07-04
Fludarabine Phosphate, Cyclophosphamide, Total Body Irradiation, and Donor Stem Cell Transplant in Treating Patients With Blood Cancer
Roswell Park Cancer Institute
Phase 2 Terminated
NCT01028716 2023-01-23
Donor Peripheral Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00303719 2020-05-12
Allogeneic Bone Marrow Transplantation Using Less Intensive Therapy
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT02145039 2019-12-26
Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Phase NA Terminated
NCT00167180 2019-07-30
Post Transplant Donor Lymphocyte Infusion
Masonic Cancer Center, University of Minnesota
Phase 2 Terminated
NCT01875237 2019-07-16
Donor Lymphocyte Infusion (DLI) of T-cells Genetically Modified With iCasp9 Suicide Gene
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT00074490 2018-12-31
Donor Stem Cell Transplant With No or Low-Intensity Chemotherapy Using Sirolimus and Treated Immune Cells to Treat Blood and Lymph Cancers
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00963872 2017-12-28
Donor Umbilical Cord Blood Transplant After Fludarabine Phosphate, Cyclophosphamide, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Cancer
Masonic Cancer Center, University of Minnesota
Phase 1/2 Terminated
NCT00376519 2017-12-02
Umbilical Cord Blood T-Regulatory Cell Infusion Followed by Donor Umbilical Cord Blood Transplant in Treating Patients With High-Risk Leukemia or Other Hematologic Diseases
Masonic Cancer Center, University of Minnesota
Phase 1 Terminated
NCT00281879 2017-09-27
Donor Stem Cell Transplant or Donor White Blood Cell Infusions in Treating Patients With Hematologic Cancer
OHSU Knight Cancer Institute
Phase 2 Terminated
NCT00719849 2017-06-14
Donor Umbilical Cord Blood Transplant in Treating Patients With Advanced Hematological Cancer or Other Disease
Fred Hutchinson Cancer Center
Phase 2 Terminated
NCT00676806 2017-06-01
A Phase II Study of Umbilical Cord Blood Transplantation
Tufts Medical Center
Phase 2 Terminated
NCT01534143 2017-04-05
High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant
Barbara Ann Karmanos Cancer Institute
Phase 2 Terminated
NCT01118013 2017-03-24
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell Transplant
Alliance for Clinical Trials in Oncology
Phase 2 Terminated
NCT01954784 2017-02-17
Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma
Case Comprehensive Cancer Center
Phase 1 Terminated
NCT00255684 2016-11-03
Fludarabine, Cyclophosphamide, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing a Donor Umbilical Cord Blood Transplant for Hematologic Cancer
University of Rochester
Phase NA Terminated
NCT01518153 2016-03-17
Planned Donor Lymphocyte Infusion (DLI) After Allogeneic Stem Cell Transplantation (SCT)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00800150 2015-06-08
Total Marrow and Total Lymph Node Irradiation, Fludarabine, and Melphalan Followed By Donor Stem Cell Transplant in Treating Patients With Advanced Hematological Cancer That Has Not Responded to Treatment
City of Hope Medical Center
Phase 1 Terminated
NCT00608517 2014-05-20
Treatment of Single or Double Umbilical Cord Trans + Graft-versus-host Disease (GVHD) Prophylaxis w/ Tacrolimus & Mycophenolate Mofetil
Vanderbilt-Ingram Cancer Center
Phase NA Terminated
NCT00827099 2012-03-23
Umbilical Cord Blood (UCB) Transplant, Fludarabine, Melphalan, and Anti-thymocyte Globulin (ATG) in Treating Patients With Hematologic Cancer
Northside Hospital, Inc.
Phase 2 Terminated